• Ionis presented new open-label extension data on June 12, 2026 at the National Lipid Association Scientific Sessions in Chicago.
• The update covered longer-term liver imaging results for olezarsen in severe hypertriglyceridemia, showing liver fat trends moving back toward baseline over time.
• Patients who previously received a lower dose showed smaller liver fat shifts when they moved to the 80 mg regimen in the extension study.
• The longer-term readout supported a favorable safety profile, supporting continued development and potential commercial positioning in sHTG.
• Retention remained high, with more than 90% of eligible participants rolling into and staying in the extension study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-025050), on June 12, 2026, and is solely responsible for the information contained therein.